Greater than 90.0% as determined by SDS-PAGE.
Proguanylin Human Recombinant produced in E. coli is a single, non-glycosylated polypeptide chain (a.a 22-115) containing 104 amino acids including a 10 a.a N-terminal His tag. The total molecular mass is 11.5kDa (calculated).
Recombinant Human Proguanylin, produced in E. coli, is a single, non-glycosylated polypeptide chain containing 104 amino acids. This includes a 10 amino acid N-terminal His tag and amino acids 22-115 of the Proguanylin sequence. The calculated molecular mass is 11.5 kDa.
Proguanylin is filtered through a 0.4 µm filter and lyophilized in deionized water at a concentration of 0.5 mg/ml.
To create a working stock solution, add deionized water to the lyophilized pellet to achieve a concentration of approximately 0.5 mg/ml and ensure complete dissolution. Please note that Proguanylin is not sterile. Before use in cell culture, it must be filtered through an appropriate sterile filter.
Lyophilized Proguanylin should be stored at -20°C. After reconstitution, aliquot the protein to avoid repeated freeze-thaw cycles. The reconstituted protein remains stable at 4°C for a limited period, showing no significant change after one week.
Purity is determined to be greater than 90.0% as assessed by SDS-PAGE.
MKHHHHHHAS VTVQDGNFSF SLESVKKLKD LQEPQEPRVG KLRNFAPIPG EPVVPILCSN PNFPEELKPL CKEPNAQEIL QRLEEIAEDP GTCEICAYAA CTGC.
The structure of proguanylin consists of a three-helix bundle, a small three-stranded β-sheet, and an unstructured linker region . The hormone guanylin is located at the COOH terminus of the prohormone and is involved in interactions with the NH2-terminal residues, which shield parts of the hormone surface . These interactions explain the negligible bioactivity of the prohormone and highlight the importance of the NH2-terminal residues in the disulfide-coupled folding of proguanylin .
Proguanylin itself exhibits negligible GC-C-activating potency . The bioactive form of the hormone is released through proteolytic processing, which involves the cleavage of proguanylin by specific proteases . This processing liberates the active hormone guanylin, which can then bind to and activate GC-C, leading to an increase in intracellular cyclic GMP (cGMP) levels . The activation of GC-C results in the secretion of fluid and electrolytes into the intestinal lumen, thereby regulating intestinal fluid balance .
Proguanylin and its active form, guanylin, have been implicated in various physiological processes, including the regulation of salt and water homeostasis through an intestinal-renal axis . The hormone’s ability to regulate GC-C activity makes it a potential target for therapeutic interventions in conditions such as chronic constipation and irritable bowel syndrome .
Recombinant proguanylin is produced using recombinant DNA technology, which involves the insertion of the proguanylin gene into a suitable expression system, such as bacteria or yeast, to produce the protein in large quantities. This recombinant form is used in research to study the structure, function, and biological activity of proguanylin and its role in various physiological processes .